Researchers at TSRI demonstrate that the immune system can cure viral infections without destroying infected cells. Nondestructive antiviral mechanisms triggered by inflammatory cytokines contribute to viral clearance, preserving organ function.
Researchers found that angiogenesis, the formation of new blood vessels, contributes to arthritic disease progression. Treatment with an integrin antagonist reduced joint swelling, pannus formation, and cartilage erosion in animal models.
Researchers at Scripps Research Institute and R.W. Johnson Pharmaceuticals have developed a new class of antibacterial agents that inhibit two-component signal transduction systems, a key regulatory mechanism in bacterial virulence. These inhibitors show promise as a potential tool against antimicrobial-resistant pathogens.
Researchers at TSRI uncover a natural mechanism that regulates angiogenesis, a process involved in cancer growth. A recombinant protein fragment, PEX, is developed to block angiogenesis and tumor growth in an experimental model, offering a potentially novel therapeutic approach.
Researchers create first commercially available catalytic antibody, which can catalyze aldol reactions with broad substrate range. This breakthrough addresses long-standing question of protein-catalyst efficiency.
A portable, hand-held biosensor has been developed to detect a wide range of medically important chemical compounds. The device, capable of detecting tiny concentrations of specific molecules, may represent a new type of practical and affordable device for various medical applications.
Researchers have solved the structure of the active site of the enzyme responsible for producing nitric oxide, a crucial signaling molecule involved in various physiological processes. The discovery provides insight into how NO production is controlled and may lead to the development of new drugs to modulate its activity.